Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calopocarpin SCHEMBL29411831 | 0.89 | PTPN1 (0.69) | PTPN1CYP3A4MAOAMAOB | |
| Calopocarpin SCHEMBL30659500 | 0.89 | PTPN1 (0.69) | PTPN1CYP3A4MAOAMAOB | |
| SCHEMBL29619822 | 0.82 | PTPN1 (0.67) | PTPN1TYR | |
| SCHEMBL21168205 | 0.77 | MAOA (0.64) | PTPN1CYP3A4MAOAMAOBTYR | |
| SCHEMBL31237248 | 0.77 | MAOA (0.64) | PTPN1CYP3A4MAOAMAOBTYR | |
| SCHEMBL32889277 | 0.77 | PTPN1 (0.79) | PTPN1TYR | |
| SCHEMBL29473025 | 0.75 | MAOA (0.64) | PTPN1CYP3A4MAOAMAOBMEN1 | |
| Medicarpin SCHEMBL2812444 | 0.75 | MAOA (0.78) | PTPN1CYP3A4MAOAMAOBTDP1 | |
| Demethylmedicarpin SCHEMBL31663447 | 0.75 | MAOA (0.78) | PTPN1CYP3A4MAOAMAOBTDP1 | |
| Demethylmedicarpin SCHEMBL29843376 | 0.75 | MAOA (0.78) | PTPN1CYP3A4MAOAMAOBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | disclosed |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | PTPN1 1563/4885CYP3A4 4148/4885MAOA 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.